Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462719 · ClinicalTrials.gov registry record · Phase 3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
A Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT03462719 is a Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 211 participants, below the 472-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03462719, a Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Ibrutinib
- DRUG Chlorambucil
- DRUG Ibrutinib (as Subsequent Therapy)
Study Locations (20)
Other
- Institut - Jules Bordet - Anderlecht
- ZNA Stuivenberg - Antwerp
- Universitair Ziekenhuis Gent - Ghent
- Virga Jessa Ziekenhuis - Hasselt
- UZ Leuven Gasthuisberg - Leuven
- Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika - Brno
- Fakultni nemocnice Hradec Kralove - Hradec Králové
- Fakultni Nemocnice Ostrava - Ostrava
- Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni - Pilsen
- Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie - Prague
- Aalborg University Hospital - Aalborg
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
Ontario
- Juravinski Cancer Centre - Hamilton
- The Ottawa Hospital - General Campus - Ottawa
Quebec
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont - Montreal
- Jewish General Hospital - Montreal
Kentucky
- Norton Cancer Institute - Louisville
New Jersey
- John Theurer Cancer Center - Hackensack
North Carolina
- Novant Health - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2029-04-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462719
The ClinicalTrials.gov registry entry for NCT03462719 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (55% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Lymphocytic, Chronic, B-Cell appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT03462719 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT03462719 about?
NCT03462719 is a clinical study titled "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)". The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
What is the current status of trial NCT03462719?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2018-04-17. Estimated completion is 2029-04-05.
What conditions does trial NCT03462719 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic, B-Cell.
What interventions are being tested in trial NCT03462719?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Ibrutinib (DRUG), Chlorambucil (DRUG), Ibrutinib (as Subsequent Therapy) (DRUG).
Who is sponsoring clinical trial NCT03462719?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03462719 being conducted?
This trial has 20 study locations across Kentucky, New Jersey, North Carolina, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Chronic, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RECRUITING · Phase 3
-
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
RECRUITING · Phase 1
-
Family Study of Lymphoproliferative Disorders
RECRUITING
-
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.